Aviragen Therapeutics, Inc. (NASDAQ:AVIR) Files An 8-K Financial Statements and Exhibits


Aviragen Therapeutics, Inc. (NASDAQ:AVIR) Files An 8-K Financial Statements and Exhibits
Item 9.01

Financial Statements and Exhibits.



99.1 Press Release dated November 29, 2017

Aviragen Therapeutics, Inc. Exhibit
EX-99.1 2 ex_101199.htm EXHIBIT 99.1 ex_101199.htm Exhibit 99.1     PRESS RELEASE     IMMEDIATE RELEASE       Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma     ATLANTA,…
To view the full exhibit click here

About Aviragen Therapeutics, Inc. (NASDAQ:AVIR)

Aviragen Therapeutics, Inc., formerly Biota Pharmaceuticals, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.